Fundraising FoxPortal Innovations — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications.
BiotechHealthtechHouston, US
Kyoji Tsuchikama(Executive Officer, Director, Promoter)Michael Torres(Executive Officer, Director, Promoter)
BoardWilliam F. McKeon(Director)Damir Illich(Director)Patrick James Crutcher(Director)
Co-investorsTMC Venture FundPortal
Synaptrix develops NOVABLOC, a non-opioid neuromodulation therapy that uses electrical stimulation to provide targeted, long-lasting postoperative pain relief.
BiotechDigital HealthMedical DevicesAlpharetta, US
Shyamy Sastry(Executive Officer, Director)
BoardDoug Reed(Director)Robert Crutchfield(Executive Officer, Director)Anita Watkins(Director)inKurt Jacobus(Director)in
Co-investorsHatteras Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.